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LEOPARD  syndrome  is a phenotypic  expression  of  mutations  in several  genes:  PTPN11,  RAF1,  and  BRAF.
All  these  genes  are  responsible  for  Ras/MARK  signaling  pathway,  which  are  important  for cell  cycle  regula-
tion,  differentiation,  growth,  and  aging.  Mutations  result  in anomalies  of skin,  skeletal,  and  cardiovascular
systems.  The  LEOPARD  syndrome  means  lentigines,  electrocardiographic  conducting  abnormalities,  ocu-
lar hypertelorism,  pulmonary  stenosis,  abnormal  genitalia,  retarded  growth,  and  deafness.  Mutations
affect  tyrosine  proteases,  which  are  included  in  the  signal  pathway  between  the  cell  membrane  and  the
nucleus.  This  rare  autosomal  dominant  disorder  is  characterized  by  high  variability  of clinical  manifesta-
tions.  Usually  only  lentigines  are  common.  Clinical  diagnosis  is based  on  lentigines  and 2 other  symptoms;
in cases  without  lentigines  – 3 symptoms  and  at least  one  affected  ﬁrst-line  relative.  Herein,  we report
the  case  of 17-year-old  male  who  had  idiopathic  hypertrophic  cardiomyopathy  with  left  ventricular
obstruction,  and  supraventricular  and  ventricular  extasystoles,  class  IVa,  left  bundle  branch  block,  as  a
life-threatening  manifestation  of  LEOPARD  syndrome.  For  the  treatment  of  cardiac  manifestations  of  this
syndrome,  the  patient  underwent  two  interventions:  (1) mitral  valve  replacement  by mechanical  valve
Optiform  number  27  with  surgical  resection  of  left  ventricular  outﬂow  tract and  subaortic  membrane
excision;  (2)  implantable  cardioverter-deﬁbrillator  therapy.
<Learning  objective:  Explain  the  abbreviation  L.E.O.P.A.R.D.  (Lentigines,  Electrocardiographic  conduct-
ing abnormalities,  Ocular  hypertelorism,  Pulmonary  stenosis,  Abnormal  genitalia,  Retarded  growth,  and
Deafness).  Suspect  the  signs  of  L.E.O.P.A.R.D.-syndrome.  Realize  the  etiology.  Evaluate  probability  of  this
congenital  disease  on the  ground  of  the  clinical  manifestations  and  laboratory  data.  Measure  the  signif-
icance  for  health  of  changes  of  organs  and  systems.  Choose  the  main  and  dangerous  manifestation  of
Selec
2  JapL.E.O.P.A.R.D.-syndrome.  
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LEOPARD is an acronym for this syndrome’s manifestations
Lentigines,ECG conducting abnormalities, Ocular hypertelorism,
ulmonary stenosis, Abnormal genitalia, Retarded growth and
eafness.). This acronym was introduced by Gorlin in 1969. LEOP-
RD syndrome is also known as Gorlin syndrome II, Lentiginosis
rofusa syndrome or Cardiocutaneous syndrome, and caused by
ene mutation. In 1936 Zeisler and Becker described the syn-
rome in a 24-year-old woman, who suffered from progressive
eneralized lentigines, hypertelorism, pectus carinatum and prog-
athism. Rosen reported about the ﬁrst familial cases in twins;
ipkin reported about 8 persons from a large 3-generation pedi-
ree. The association of the syndrome with cardiac abnormalities
nd short stature was made by Moynahan in 1962. Frequency of
∗ Corresponding author. Tel.: +7 916 552 02 46; fax: +7 499 246 89 88.
E-mail address: krizaliy@mail.ru (M.  Betekhtin).
878-5409/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2012.10.006t  the  best  way  for treatment  such  patients.>
anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
this disease is rare and is not yet possible to assess the epidemiol-
ogy.
Case report
In January 2012 the 17-year-old male was  hospitalized for
mitral valve replacement and implantation of cardioverter deﬁ-
brillator. On physical examination, he was 164 cm, 41 kg, with an
asthenic ﬁgure. There were multiple lentigines on the skin, located
throughout the body, legs 2 spots (dark-brown) larger than 1.5 cm,
hyper elasticity skin, acrocyanosis of the lower extremities, a few
keloid scars after surgery, and several atrophic scars. There was
facialdys morphism and low-setears. In addition, there was  acar-
inate chest, kyphoscoliosis of the thoracolumbar spine, and joint
hyper mobility (Fig. 1a and b). The heart rate was  72 per min  and the
blood pressure was 90/50 mmHg. His medical history included the
fact that he was  apremature infant with idiopathic hypertrophic
subaortal stenos is. Chest deformation and dark-brown spots on
the legs were diagnosed after birth. Multiple lentigines on the
vier Ltd. All rights reserved.
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eFig. 1. (a and b) 17-year-old
ace and body appeared since he was 6 years of age. At the same
ime, chest deformation was aggravated and feet deformations
ere noted. During physical development, retardation of growth
as marked. The patient was noted to have signiﬁcant deterio-
ation including reduced tolerance to physical and mental stress,
eart disturbances, and brief episodes of unconsciousness since
002.
The clinical evaluation of LEOPARD syndrome was based on an
lectrocardiogram (ECG), dynamic ECG (Holter monitor), a chest
Fig. 2. Electocardiogram showing sinus rhythm with horizontal axis of the heart with LEOPARD syndrome.
X-ray, an echocardiogram, and genetic testing. He was hospitalized
for implant able cardioverter-deﬁbrillator therapy.
During the hospital stay, ECG showed: electrical axis of heart
deviation to the left, left bundle branch block, left a trial hypertro-
phy, left ventricular hypertrophy, and overload (Fig. 2).
On echocardiography there was left a trial dilation; normal and
uniform global contractility; left ventricular hypertrophy of free
right ventricular wall and septum, with obstruction outﬂow tract
(Vmax = 5.4 m/s, peak gradient = 117/61 mmHg); right atrium and
t, left bundle branch block, and left atria and left ventricular hypertrophy.
S. Dzemeshkevich et al. / Journal of Car
Fig. 3. Two-dimensional echocardiogram after mitral valve replacement: showing
a  dilated left atrium and left ventricle hypertrophy of free right ventricular wall and
septum. Color Doppler showed hemodynamic parameters and function of prosthetic
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They are some what compacted, sometimes raised above the skinitral valve is not violated. LA, left atrium; LV, left ventricle; RA, right atrium; RV,
ight ventricle.
ight ventricle were of normal size; severe mitral regurgitation;
ild tricuspid valve regurgitation; and diastolic dysfunction of left
entricular type III (Fig. 3).
Dynamic ECG (Holter monitor) showed sinus tachycardia
hroughout the recording period; normal physiological heart rate
ecrease during night sleep; 25 supraventricular extasystoles and
18 ventricular extasystoles – class IVa.
Chest X-ray examination showed signs of pulmonary conges-
ion. Heart increased in size due to both atria and right ventricle.
eft atria shadow deﬂected barium-ﬁlled gullet in an arc of large
adius, beyond the shadow of the right contour of heart, on the left
ontour of the heart there was marked bulging of the arc of the left
trial auricle. The functional features of mitral insufﬁciency were
etermined.
Computed tomography showed that media stinal organs were
ell differentiated in the carinate chest. Heartincreasedin size.
ericardium with separation layers on the parietal wall of the right
entricle to 9.0 mm.  The superior vena cava – 1.7 cm,  pulmonary
runk – 3.1 cm,  the right and left pulmonary artery – 2.1 cm and
eft – 2.1 cm,  respectively. The inferior vena cava – 2.6 cm.  Left ven-
ricular end-diastolic dimension – 2.2 cm,  right ventricle – 1.9 cm,
ight atrium – 4.4 cm × 3.9 cm.  Thickness of ventricular septum
basalsegments) in diastole: anterior – 2.6 cm,  inferior – 2.5 cm.
he thickness of the ventricular myocardium: anterolateral –
.3 cm,  inferolateral – 2.3 cm.  The thickness of the left ventricular
yocardiumin the apical partindiastole – 0.97 cm.  Left ventricu-
aroutﬂow tract – 18 mm,  in the lumen of the vena cava superior
nd right a trial cavity are linear structure of the electrodes.Genetic study showed mutations in exon 12 of the gene PTPN11
nd changes in the adjacent intron regions of the gene RAF1 (5, 6,
3, 15 introns).diology Cases 7 (2013) e37–e41 e39
Medications the patient was  taking before surgery were: beta-
blockers, diuretics, and antiarrhythmics drug. Although the patient
was compensated by drug therapy, the need for surgery was nec-
essary in view of the episodes of loss of consciousness.
The operation of mitral valve replacement by mechanical
valve with surgical resection of left ventricular outﬂow tract and
subaortic membrane excision was  performed successfully. After
that, a dual-chamber cardioverter deﬁbrillator (ICD) with right
ventricular and right atria electrodes was implanted. Implanted
ICD systems are an effective way  of preventive therapy for life-
threatening arrhythmias and sudden death [3,10,11], and therefore
in the above case, the ﬁnal stage of surgery was implanted ICD.
When checking the value of ICD exhibited mode DDD, base fre-
quency 50–130 min, the threshold of stimulation: right atrium –
0.6 V. Right ventricle – 0.6 V.
The patient was  treated with antibacterial, anti-inﬂammatory,
antianginal, antiarrhythmic, diuretic, and anticoagulant drugs.
Early postoperative period was uneventful.
Control laboratory studies have shown: activated partial throm-
boplastin time 46.9 (27–37) s, ﬁbrinogen 2.27 g/l, prothrombin
index 38.73%, international normalized ratio 2.89 (1.0–1.3). The
other indicators were normal.
Discussion
LEOPARD syndrome is a rare condition, which is caused by dif-
ferent missense-mutations in one of the 3 genes (PTPN1 = 90%,
RAF1 < 5%, BRAF < 5%) and sub sequent disturbances (Fig. 4).
One feature of the natural history of LEOPARD syndrome is an
increased risk of neoplasia. Genes responsible for the develop-
ment of the LEOPARD syndrome are a family of proto-oncogenes
and mutations in them are associated with the risk of lympho
proliferative disease [8].  For example, different mutations in the
PTPN11 gene may  cause allelic series of diseases with different
clinical phenotypes, but an increased risk of cancer. So an impor-
tant part of the follow-up of patients with LEOPARD syndrome
is a planned control of blood cell composition and consulting an
oncologist annually.
Last investigations showed molecular mechanisms of LEOPARD
syndrome, but now its prevention is possible only in experi-
ments. This rare autosomal dominant disorder is characterized
by high variability of clinical manifestations. According to some
researchers, the number of patients is much greater, and the evi-
dence of symptoms increases with age [7,11,14,17].
The title of the syndrome L.E.O.P.A.R.D. is derived from the initial
letters of the major signs and symptoms of the syndrome, according
to Gorlin et al. [2,4,5]:  Lentigo – lentigines to 100%. ECG – elec-
trocardiogram abnormalities (75–80%), among them: hypertrophy
of the left ventricle, or both ventricles (46%) [1],  appearance of Q
wave (19%), elongation of QTc (23%) and impaired repolarization
(42%) [9],  conduction disorders (23%) and P-wave abnormalities
(19%). Ocular hypertelorism – 75%. Pulmonic stenosis – 95%. Abnor-
malities of genitalia – 50%. Genital anomalies include agenesis
or hypoplasia of the gonads andhypogonadism. Retardation of
growth – 40–50%. In 50% of cases there are winged scapula, 35% –
cervical pterygium. Notes funnel or pigeon chest deformity. Deaf-
ness – 15–25% [2].
Clinical diagnosis is based on lentigines and 2 other symptoms,
in cases without lentigines – 3 symptoms and at least one affected
ﬁrst-line relative [22,23].
Lentigo is usually multiple spots ranging in size from 1.5 mm to
2 cm in diameter, round orelongated, yellowish or brownish-black.surface. Edges of the spots have the shape of teeth or are smooth.
Lentigo spots can affect not only the skin, but mucous membranes.
Common forms of lentigines often deﬁned aslentiginosis. Such
e40 S. Dzemeshkevich et al. / Journal of Cardiology Cases 7 (2013) e37–e41
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(Fig. 4. Disturbances of intracellular sig
atients may  have thousands of lentigines by the time they reach
uberty. Congenital lentiginosis is inherited in an autosomal
ominant manner and is characterized by the appearance on
he skin of the child of many small round brown spots. Biopsy
f lentigo shows a canthos is, a large amount of melanin and
elanocytesin the basal layer of the epidermis, in the upper part
f the derm is there are melanophores and small perivascular
nﬁltrates of lymphocytes [13,14,22].  The etiopathogenesis of this
linical feature remains unknown. Some authors consider that
EOPARD syndrome patients have high melanocytic activity and
ncreased beta-adrenergic effector activity in the myocardium
22]. Perhaps a peculiarity of exchange of tyrosine, from which
elaninis formed, also plays a role.
Inun complicated and feebly marked cases of lentiginos is
reatment is not obligatory. Since lentiginesare subject toconstant
rauma, it is recommended to remove them by surgery or with a
aser or cryodestruction. Usage of topical creams is also possible.
ream hydroquinone and cream tretinoin can brighten up lentig-
nes during 2–4 months.
Multiple lentigines syndrome is an indicator of both LEOPARD
nd many genetic diseases that share similar etiopathogenic mech-
nisms. Despite the fact that the incidence of these diseases is
are, physicians should pay attention to the presence or absence
f lentigines.
For instance, lentigines over the entire surface of the body and
ral mucosa are also described in the Carney complex. But there are
ot lentigines on the oral mucosa in the LEOPARD syndrome [16].
Life-threatening conditions are associated with pathology of
he cardiovascular system. Cardiac abnormalities include electro-
ardiographic conduction defects and anatomical malformations;
lectrocardiographic conduction abnormalities are especially fre-
uent. Axial deviation, prolonged PR interval, left anterior
emiblock (LAH), bundle-branch block, and complete heart block
CHB) are also described [22].
Hypertrophic cardiomyopathy (HCM) is a frequent autosomal
ominant disease characterized by hypertrophy (thickening) of the
eft wall and/or right ventricle. The prevalence in a population
s not less than 0.2% (1:500 individuals). The classiﬁcation of the
merican Heart Association, 2006 [12], identiﬁes the primary HCM
developing as a result of mutations in sarcomeric protein genes)ansduction in the LEOPARD syndrome.
and secondary HCM, which is part of a symptom of many genetic
syndromes (e.g. Noonan, LEOPARD, storage diseases, etc.) [15].
HCM is found in as many as 80% of patients and sometimes
causes death, while pulmonic stenosis is present in about 40%
of patients. A variety of anomalies affecting the patient forces
doctors to use the full range of interventions, in compliance with
the existing pathology.
Patients with HCM have a high risk of ventricular tachyarrhyth-
mias and sudden cardiac death, so that all patients should undergo
risk stratiﬁcation for sudden cardiac death and the initial stages
of the survey should identify tachyarrhythmia episodes, as well as
unexplained syncope in history [3,10,21].
One of the most effective treatments for obstructive HCM is a
form of surgery [6,18].  The two  main common surgical treatments
for HCM are septal myectomy [14,18,19] and alcohol septal abla-
tion [20]. The success of the latter depends on the variability of
anatomy branches septal perforators that in 20–25% of cases do
not achieve the desired effect [19]. With common forms of HCM
and, especially when combined with other intracardiac patholo-
gies, the only method of treatment is surgery under extracorporeal
circulation.
This syndrome is still not sufﬁciently studied, and remains a
puzzle to researchers. Sometimes, there are reports of possible new
symptoms of the syndrome [24].
Due to the fact that the syndrome is rare, it is difﬁcult to deter-
mine what other symptoms can be referred to this syndrome. Since
only a small number of cases have been described, one or two cases
can signiﬁcantly change the statistics.
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